How do we ensure strategic vision and thoughtful implementation when pursuing new opportunities in science and technology?

Our guests discuss challenges around reimbursement, intellectual property, change management and the critical nature of early engagement.

Additionally, we are joined by Tamei Elliott of DIA who shares insights on key discussions and themes of the upcoming meeting in San Diego.

This is the third and final episode in our preparation for the roundtable discussion: ⁠⁠Pioneering New Frontiers: Advanced Drug Delivery Technologies and Cell/Gene Therapies in Combination Products⁠⁠ taking place at the ⁠⁠DIA 2024 Global Annual Meeting⁠⁠.

James Wabby, Global Head, Regulatory Affairs, Emerging Technologies and Combination Products, AbbVie is chairing the discussion between Rob Schulz, President and Chief operating officer of Suttons Creek, William Daunch, Chief Technology Officer, Focal Medical, Inc, Andrea Gray, Biomedical Engineer Advisor, CBER, FDA, and Michael Lehmicke, Senior Vice President, Science and Industry Affairs, Alliance for Regenerative Medicine.

Lori Ellis will be covering DIA Global Annual meeting 2024, June 16-20 in San Diego.

Host

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, ⁠⁠⁠BioSpace⁠⁠⁠

Guests

⁠⁠James Wabby⁠⁠, Global Head, Regulatory Affairs, Emerging Technologies and Combination Products, ⁠⁠AbbVie, United States⁠⁠

⁠⁠Rob Schulz⁠⁠, President and COO, ⁠⁠Suttons Creek, Inc., United States

Tamei Elliott, Associate Director, Scientific Programs (Americas), DIA

BioSpace x DIA: Robust Integrated Regulatory Strategies

BioSpace

BioSpace x DIA: Robust Integrated Regulatory Strategies